NCT06887023Completed
Clinicopathologic Characteristics, Progression, and Prognostic Analysis of IPNB
Clinicopathologic Characteristics, Progression, and Prognostic Analysis of Intraductal Papillary Neoplasm of Bile Duct
Source: ClinicalTrials.gov · Last updated 20 Mar 2025
Brief summary (registry, in English)
The main aim of this observational study is to understand the clinicopathological and prognostic information of IPNB, a rare tumor. The participants have already received treatment during their previous routine medical management and took part in follow - up. We will look into their survival information after previous medical visits and treatment.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 118 (actual)
- First submitted
- 14 Mar 2025
- Start date
- 1 Dec 2024
- Primary completion date
- 15 Jan 2025
- Lead sponsor
- The First Hospital of Jilin University
- Diseases
- Childhood cancers
- NCT number
- NCT06887023
What you commit to
- Study type: Observational
- Participants enrolled: 118
- From 1 Dec 2024 to the primary completion date, 15 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- coexisting malignant tumors of other digestive system organs
Other
- missing other essential clinical data
Who the study is looking for
- IPNB with or without malignant transformation was confirmed by pathological examination
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Hospital of Jilin University Coordinator of this site? Confirm its status | Changchun | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.